STAT+: 89bio treatment reduces liver scarring in patients with NASH, meeting study goals
89bio said its experimental treatment improved liver scarring at more than three times the rate of placebo in patients with the fatty liver disease known as NASH.
Biotech company 89bio said Wednesday that its experimental treatment improved liver scarring at more than three times the rate of placebo without worsening other symptoms of patients with the fatty liver disease known as NASH.
The results met the main goal of a mid-stage clinical trial, with the potential for less frequent injections than a similar experimental treatment being developed by a competing drugmaker.
What's Your Reaction?
